ER4017 (hydroxypropyltetrahydropyrantriol)
PreclinicalSmall molecule
ER4017 (hydroxypropyltetrahydropyrantriol) is one of 12 small molecule programs targeting Elderly. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Elderly
#DrugCompanyPhaseTrials
1Venclexta
AbbVieApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Azacytidine
AArog Pharmaceuticals, Inc.
Phase 2
R-Gemox
HHutchmed
Phase 2
Influenza Vaccine
NovartisPreclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]